维奈克拉50毫克、去甲基化药物与伏立康唑或泊沙康唑治疗急性髓系白血病的疗效
Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia.
作者信息
Diebold Kendall, Parker Devan, Worth Sarah, Espinoza-Gutarra Manuel, Vachhani Pankit, Bachiashvili Kimo, Rangaraju Sravanti, Mohty Razan, Bhatia Ravi, Jamy Omer
机构信息
Division of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
出版信息
EJHaem. 2025 May 6;6(3):e70049. doi: 10.1002/jha2.70049. eCollection 2025 Jun.
BACKGROUND
Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.
METHODS
We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole ( = 23) or voriconazole ( = 95).
RESULTS
We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.
CONCLUSION
HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.
CLINICAL TRIAL REGISTRATION
The authors have confirmed clinical trial registration is not needed for this submission.
背景
在急性髓系白血病（AML）中，关于低甲基化药物（HMA）+50毫克维奈克拉（VEN50）联合伏立康唑和泊沙康唑的真实世界证据有限。
方法
我们评估了新诊断的AML患者接受HMA+VEN50联合泊沙康唑（n = 23）或伏立康唑（n = 95）治疗的结果。
结果
我们报告，HMA+VEN50联合任何一种唑类药物治疗的缓解率与VIALE - A试验中描述的相似。使用任何一种强效CYP3A4抑制剂将VEN剂量降至50毫克均未影响联合用药的疗效。
结论
HMA+VEN50联合泊沙康唑或伏立康唑产生的反应与先前报道的更高剂量VEN相当。
临床试验注册
作者已确认本次提交无需进行临床试验注册。
Zotero 插件